The overexpression of choline-kinase alpha (CKα) promotes aberrant choline metabolism in epithelial ovarian cancer, thus increasing phosphocholine- and total choline-containing compounds. Previous findings had shown that silencing CKα impacted cell proliferation, migration and invasion, and CKα was hypothesized to be a potential new therapeutic target for ovarian cancer.
Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories.
Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.
Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) targeting moiety through a linker reported to be useful for the treatment of cancer.
Ovarian cancer stem cells are characterized by high activity of aldehyde dehydrogenase (ALDH) enzyme as well as high expression of CD133 marker, and the combination of both correlates with poor prognosis in patients.
Liquid biopsy typically means blood testing, but several companies presenting at Biomed Israel May 21-23 have developed diagnostics that look to other, even less invasive options, and ever broader applications. Nevia Bio Ltd. is using vaginal secretions to detect ovarian cancer, while Early OM Ltd. and Nucleix Ltd. analyze urine for cancer biomarkers.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.
Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
